Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Drug Product Manufacturing
  6.  » Innovative Strategies To Maintain Product Integrity In Biologic And Biosimilar Clinical Studies

Innovative Strategies To Maintain Product Integrity In Biologic And Biosimilar Clinical Studies

Summary: Delays encountered during clinical studies can have a serious impact on competitive advantage, speed to market and the availability of lower-cost alternatives for patients. Specialized expertise in cold chain shipping and logistics are critical to avoid costly delays and potential for patient harm resulting from an interruption or delay in necessary clinical supply. Maintaining product integrity and reliability of supply can be especially challenging for biologic and biosimilar studies which will almost certainly require cold chain handling.

Click here to download white paper.

Related Topics